This is an amended filing · View original →
GC Biopharma Corp. [Amended] Single Sales/Supply Contract
GAI summary · Not investment advice
GC Biopharma corrected the amount of its Brazil export supply contract with BLAU Farmaceutica S.A. to KRW 142.1 billion.
Contract amount
KRW 142.1 billion
Key facts
- Contract details
- Brazil export supply contractOther sales/supply contract
- Recent revenue
- KRW 1.7 trillionBased on FY2022 consolidated financial statements
- % of revenue
- 8.30%
- Counterparty
- BLAU Farmaceutica S.A.
- Supply region
- Brazil
- Contract period
- 2023-06-30 to 2028-06-29
- Payment terms
- No down payment or advance paymentNo down payment or advance payment
- Contract date
- Jun 30, 2023
Commentary
AI commentary · Not investment advice
What happened
GC Biopharma corrected the contract amount of its export supply agreement with BLAU Farmaceutica S.A. of Brazil to KRW 142.1 billion. The contract was signed on June 30, 2023, and runs from June 30, 2023 to June 29, 2028. The supply region is Brazil, and the filing was received on November 2, 2026.
In the company's terms
Relative to the company, the contract amount equals 8.30% of its most recent revenue of KRW 1,711.3 billion. It is 9.2% of market capitalization as stated in the filing. The payment terms specify no down payment or advance payment.
Earlier Single Sales/Supply Contract filings from this company
| Filed | Counterparty | Contract amount | % of revenue |
|---|---|---|---|
| 26.11.022026.11.02 | VaxThera Zona Franca S.A.S. | KRW 59.2 billion | 2.97% |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist